The central hypothesis of this proposal is that there is an abnormal qualitative and quantitative distribution of gangliosides in malignant gliomas and medulloblastomas, perhaps similar to fetal brain, but different from normal adult tissues, especially normal adult neurons and glia. Biochemical analyses will first characterize and quantitate the types of gangliosides present in a large series of malignant human glioma biopsies, permanent glioma derived cell lines, and athymic mouse and rat-human glioma xenografts and detemine if unique gangliosides are present which are characteristics of gliomas. This methodology will then be utilized to similarly characterize and quantitate the types of gangliosides present in our models of human medulloblastoma.
Our specific aims are: a) To produce monospecific monoclonal antibodies directed against the unique D-54 MG mono- and disialogangliosides 3'-iso-LM1, LD1, and GM3, GD3, GM3, GD2 and additional unique gangliosides defined in the course of this study; b) to define the distribution in human glioma tissue of these gangliosides qualitatively at the cellular level using immunocytochemistry with monoclonal antibodies directed against 3'-iso-LM1, LD1, GM3, GD3, GM2, GD2 and each new unique ganglioside and quantitatively at the tissue level using analytic techniques and thin layer chromatography on multiple human gliomas with varying cytomorphologies and degrees of malignancy; c) to use these monoclonal antibodies directed against 3'-iso-LM1, LD1, GM3, GD3, GM2, GD2 and each new unique ganglioside to examine the function of the defined gangliosides in cell-cell interactions, clonogenicity, and invasion utilizing in vitro and in vivo assays of cell growth, adhesion, and invasiveness; d) to use those monoclonal antibodies directed against 3'-iso-LM1, LD1, GM3, GD3, GM2, GD2 or any of the new unique gangliosides exhibiting broad reactivity within and among human gliomas and minimal normal tissue reactivity to demonstrate radioimaging and radiotherapeutic efficacies in the nude mouse - human glioma xenograft model; e) to define similarly the potentially abnormal qualitative and quantitative distribution of gangliosides in medulloblastoma, using the most complete and rigorously characterized models for this tumor extant and to execute similar studies as with gliomas. These studies will, therefore define the biodistribution of the altered gangliosides in human glioma and medulloblastoma, contribute to the understanding of the functional significance of gangliosides in adhesion, growth, and invasion, and establish pre-clinical efficacy of radiolabeled anti-ganglioside antibodies in glioma and medulloblastoma radioimaging and radiotherapy to aid in selecting monoclonal antibodies for clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37CA011898-24
Application #
2086000
Study Section
Special Emphasis Panel (NSS)
Project Start
1976-12-01
Project End
1996-03-31
Budget Start
1994-04-01
Budget End
1995-03-31
Support Year
24
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Duke University
Department
Pathology
Type
Schools of Medicine
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Koroukian, Siran M; Bakaki, Paul M; Golchin, Negar et al. (2015) Breast Cancer Stage and Treatment Among Ohio Medicaid Beneficiaries With and Without Mental Illness. J Oncol Pract 11:e50-8
Chandramohan, Vidyalakshmi; Mitchell, Duane A; Johnson, Laura A et al. (2013) Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. Future Oncol 9:977-90
Chandramohan, Vidyalakshmi; Bao, Xuhui; Keir, Stephen T et al. (2013) Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy. Clin Cancer Res 19:4717-27
Piao, Hailan; Kuan, Chien-Tsun; Chandramohan, Vidya et al. (2013) Affinity-matured recombinant immunotoxin targeting gangliosides 3'-isoLM1 and 3',6'-isoLD1 on malignant gliomas. MAbs 5:748-62
Chandramohan, Vidyalakshmi; Bao, Xuhui; Kato Kaneko, Mika et al. (2013) Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors. Int J Cancer 132:2339-48
Koroukian, Siran M; Bakaki, Paul M; Golchin, Negar et al. (2012) Mental illness and use of screening mammography among Medicaid beneficiaries. Am J Prev Med 42:606-9
Reardon, David A; Desjardins, Annick; Peters, Katherine B et al. (2012) Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. J Neurooncol 107:155-64
Reardon, David A; Desjardins, Annick; Vredenburgh, James J et al. (2012) Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. Cancer 118:4759-67
Jiao, Yuchen; Killela, Patrick J; Reitman, Zachary J et al. (2012) Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 3:709-22
Lou, Emil; Sumrall, Ashley L; Turner, Scott et al. (2012) Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol 109:63-70

Showing the most recent 10 out of 267 publications